M
Maria Carmona-Iragui
Researcher at Autonomous University of Barcelona
Publications - 76
Citations - 2093
Maria Carmona-Iragui is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Dementia & Medicine. The author has an hindex of 21, co-authored 52 publications receiving 1279 citations. Previous affiliations of Maria Carmona-Iragui include Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
Juan Fortea,Eduard Vilaplana,Maria Carmona-Iragui,Bessy Benejam,Laura Videla,Isabel Barroeta,Susana Fernández,Miren Altuna,Jordi Pegueroles,Victor Montal,Sílvia Valldeneu,Sandra Giménez,Sofía González-Ortiz,Laia Muñoz,Teresa Estellés,Ignacio Illán-Gala,Olivia Belbin,Valle Camacho,Liam R. Wilson,Tiina Annus,Ricardo S. Osorio,Sebastián Videla,Sylvain Lehmann,Anthony J. Holland,Daniel Alcolea,Jordi Clarimón,Shahid Zaman,Shahid Zaman,Rafael Blesa,Alberto Lleó +29 more
TL;DR: Alzheimer's disease in individuals with Down syndrome has a long preclinical phase in which biomarkers follow a predictable order of changes over more than two decades, which makes this population a suitable target for Alzheimer's disease preventive treatments.
Journal ArticleDOI
Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Daniel Alcolea,Pablo Martinez-Lage,Pascual Sánchez-Juan,Javier Olazarán,Carmen Antúnez,Andrea Izagirre,Mirian Ecay-Torres,Ainara Estanga,Montserrat Clerigue,Maria Concepción Guisasola,Domingo Sánchez Ruiz,Juan Marín Muñoz,Miguel Calero,Rafael Blesa,Jordi Clarimón,Maria Carmona-Iragui,Estrella Morenas-Rodríguez,Eloy Rodríguez-Rodríguez,José Luis Vázquez Higuera,Juan Fortea,Alberto Lleó +20 more
TL;DR: The findings suggest that inflammation in the CNS increases in normal aging and is intimately related to markers of neurodegeneration in the preclinical stages of AD and SNAP.
Journal ArticleDOI
Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
Juan Fortea,Maria Carmona-Iragui,Bessy Benejam,Susana Fernández,Laura Videla,Isabel Barroeta,Daniel Alcolea,Jordi Pegueroles,Laia Muñoz,Olivia Belbin,Mony J. de Leon,Aleksandra Maleska Maceski,Christophe Hirtz,Jordi Clarimón,Sebastián Videla,Constance Delaby,Sylvain Lehmann,Rafael Blesa,Alberto Lleó +18 more
TL;DR: The utility of plasma NfL for the early detection of Alzheimer's disease in Down syndrome in clinical practice and clinical trials is supported and the diagnostic performance of plasma and CSF biomarkers are investigated.
Journal ArticleDOI
Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
Juan Fortea,Eduard Vilaplana,Daniel Alcolea,Maria Carmona-Iragui,Maria Belén Sánchez-Saudinós,Isabel Sala,Sofía Antón-Aguirre,Sofía González,Santiago Medrano,Jordi Pegueroles,Estrella Morenas,Jordi Clarimón,Rafael Blesa,Alberto Lleó +13 more
TL;DR: The objective was to assess the relationships between core cerebrospinal fluid biomarkers and cortical thickness in preclinical Alzheimer disease (AD) and to establish a causal relationship between CSF and CTh.
Journal ArticleDOI
Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease
Daniel Alcolea,Maria Carmona-Iragui,Marc Suárez-Calvet,M. Belen Sánchez-Saudinós,Isabel Sala,Sofía Antón-Aguirre,Rafael Blesa,Jordi Clarimón,Juan Fortea,Alberto Lleó +9 more
TL;DR: The inflammatory marker YKL-40 is increased in different neurodegenerative diseases, even in early stages, and it correlates with biomarkers of Neurodegeneration, suggesting that inflammation is a common feature in AD and FTD.